MedTrace Logo

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

NCT01211457 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-07-16

No results posted yet for this study

Summary

This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS

Conditions

Interventions

DRUG

sapacitabine and decitabine (Part 1 - completed)

decitabine will be administered in alternating cycles with sapacitabine

DRUG

sapacitabine and venetoclax (Part 2 - recruiting)

sapacitabine will be administered concomitantly with venetoclax

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Cyclacel Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Hagop M Kantarjian, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-17
Primary Completion
2020-06-20
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01211457 on ClinicalTrials.gov